Business
BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 st...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout\n\n\n\n\n\n\n Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)\n \n\n\n\n\n\n Enrollment exceeding expectations with strong clinical site and patient interest\n \n\n\n\n\n\n Topline interim data readout expected in 1H2026\n \n\n\n\n\n\n Phase 3 combination regimen continues under FDA Fast Track designation\n \n\n\n\n\n PHILADELPHIA and VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 clinical study has screened over 230 and enrolled over 160 patients. BriaCell anticipates reporting topline data as early as 1H2026.\n \n\n Interim data will be analyzed once 144 patient events (deaths) occur. Positive results from this pivotal study could support full approval and marketing authorization of Bria-IMT™ in patients with metastatic breast cancer.\n \n\n BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT, plus an immune check point inhibitor versus physician’s choice in\n \n a\n \n dvanced metastatic\n \n b\n \n reast\n \n c\n \n ancer (Bria-ABC).\n \n\n “The pace of patient enrollment in our pivotal Phase 3 study has exceeded expectations underscoring the strong engagement of participating sites and the high level of interest from patients and investigators,” stated Dr. William V. Williams, BriaCell’s President & CEO. “We look forward to collecting, analyzing and sharing the Phase 3 data with the U.S. FDA in the coming months as we continue working to bring hope to patients with metastatic breast cancer who face an urgent medical need.”\n \n\n\n\n About BriaCell’s Pivotal Phase 3 Clinical Study of Bria-IMT Combination Regimen in MBC patients\n \n\n\n\n BriaCell’s pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor (CPI) in metastatic breast cancer is ongoing.\n \n\n Interim data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune ...